Latest Breaking News On - Prnewswire lipella pharmaceuticals inc - Page 1 : vimarsana.com

FDA Grants Orphan Designation for Lipella's LP-310 Drug Candidate for Oral Graft-versus-Host Disease

Lipella Pharmaceuticals' LP-310 clinical stage asset is formulated for delivering active agents to the oral cavity for diseases of the mouth including oral lichen planus and oral graft-versus-host disease PITTSBURGH, Nov. 10, 2023 /PRNewswire/ Lipella Pharmaceuticals Inc. (Nasdaq: LIPO), a clinical stage pharmaceutical company addressing serious diseases with significant unmet need based in Pittsburgh, PA, announced today that it has been granted "Orphan Drug Designation" from the U.S. Food

Lipella Pharmaceuticals Announces Closing of $2 Million Private Placement Priced At-The-Market Under Nasdaq Rules

Lipella Pharmaceuticals Announces FDA Clearance of IND for LP-310 for Oral Lichen Planus

/PRNewswire/ Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing.

Lipella Pharmaceuticals' Phase 2a Clinical Study Results Published in the Journal of Urology and Nephrology

Article highlights results from successful Phase 2a clinical trial for lead candidate, LP-10 Lipella expects to initiate Phase 2b clinical trial in LP-10 in early 2024 PITTSBURGH, Pa., Sept. 21,.

Lipella Pharmaceuticals Reports First Quarter 2023 Financial Results and Corporate Update

/PRNewswire/ Lipella Pharmaceuticals Inc. (Nasdaq: "LIPO") ("Lipella," "our, "us" or the "Company"), a clinical-stage biotechnology company addressing.